LUND, Sweden & EVRY, France--(BUSINESS WIRE)--Hansa Biopharma, “Hansa” (Nasdaq Stockholm: HNSA) and Genethon, a pioneer and a leader in gene therapy research and development for rare genetic diseases, ...

Genethon, a non-profit research organization and world leader in gene therapies for rare diseases, is marking World Duchenne Muscular Dystrophy Day on September 7, 2024, by reiterating its 35-year ...

PARIS, January 26, 2026--(BUSINESS WIRE)--Genethon, a unique non-profit gene therapy R&D organization founded by the French Muscular Dystrophy Association (AFM-Telethon), began the new year with an ...

PARIS, January 14, 2026--(BUSINESS WIRE)--Genethon, a leading laboratory in gene therapy for rare diseases, today announced that it has entered into an exclusive, worldwide licensing agreement with ...

Sarepta Therapeutics has announced a new collaboration with Genethon for gene therapy research in efforts to develop new Duchenne muscular dystrophy (DMD) treatments. Sarepta Therapeutics has ...

PARIS, France (September 12, 2024) - Genethon, the pioneering French laboratory and leader in the research and development of gene therapies for rare diseases, announced today publication in Nature ...

ÉVRY, France and BOSTON, May 21, 2026 /PRNewswire/ -- Genethon, the French pioneer in the discovery and development of gene therapies for rare diseases, and Ampersand Biomedicines, a Flagship ...

Tuesday, April 28, during a ceremony at the Elysee Palace, Genethon, the laboratory of the AFM-Telethon, was named recipient of the Global Innovation Competition 2030 in the category 'Risk lift' The ...

Phase 3 trial clearance is based on the Phase 1/2 results demonstrating safety and efficacy of the 3x10¹³ vg/kg dose of microdystrophin, which is lower than doses used in other gene therapies for ...

Genethon, a pioneering gene therapy research organization created by the AFM-Telethon, marks Rare Disease Day February 28, 2025, by highlighting recent technological breakthroughs signaling a next ...

Genethon, dedicated to designing and developing gene therapy products for rare diseases, received this Monday 30th of November the authorization from the ANSM, the French National Agency for Medicines ...

Genethon, a worldwide pioneer and leader in research and development of gene therapy for rare genetic diseases, and Hansa Biopharma, a Sweden-based leader in IgG cleaving enzyme technology announced ...